CYTK Cytokinetics Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
05:59
Jul 27
Jul 27
Author highlights Affinity's golden run in biotech and their top 5 FBRX holding post-APGE acquisition, celebrating broad sector gains without explicit forward calls on most names.
LOW
00:07
Jul 27
Jul 27
Buy CYTK as a second-tier derisked/M&A candidate recommended for capital deployment in the current biotech setup.
MED
08:04
Jun 30
Jun 30
The tweet reports a list of stocks receiving analyst upgrades but does not state the author's own position, making it a factual research summary rather than a trade idea.
LOW
10:20
Jun 29
Jun 29
Speaker questions CYTK in response to parent post about Novartis flight patterns and M&A, but offers no personal stance or catalyst.
LOW
17:40
Jun 28
Jun 28
Author increased their ABVX position as a concentrated conviction bet on Obe commercialization at ~$8B market cap, while closing COGT and BCRX for decent returns, and notes XBI outperformance as a positive sector signal.
LOW
13:13
Jun 21
Jun 21
Author lists ELVN and CYTK as early-stage M&A candidates (<2 months post positive data), too early in the author's own framework but flagged as names to monitor for future rotation into the hot zone.
MED
00:55
Jun 21
Jun 21
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom, but it is a factual research summary without explicit author positions or forward calls.
LOW
15:09
May 29
May 29
The author highlights Chris Staral's past holdings and return under Triple Helix, but this is a historical research summary and watchlist, not an active position or forward call.
LOW
19:24
May 24
May 24
Author details bullish theses on NKTR, BCRX, and ABVX with specific catalysts and data comparisons, while closing CYTK due to margin needs.
LOW
18:19
May 19
May 19
Author adds to ABVX and NKTR positions ahead of key data, expressing bullish conviction on ABVX's high probability of meeting endpoints while holding other biotech names for later review.
HIGH
22:58
May 17
May 17
"Checkpoint Capital increased positions in ARGX, CYTK, RYTM in Q1 2026. Fund disclosure, no speaker thesis."
HIGH
14:28
May 17
May 17
Buy these biotech names after derisking events (post-data capital raises); upcoming CD data catalyst could double market capitalization in 5-6 months.
HIGH
17:44
May 07
May 07
Long CYTK from the speaker's biotech holdings; reasoning is high-level conviction.
HIGH
16:35
May 05
May 05
Re-enter long $CYTK alongside $EWTX for cardiovascular biotech exposure, with the speaker calling this a solid entry.
HIGH
20:01
May 04
May 04
Adam May's tweet "Cyto de mayo" is a pun referencing Cytokinetics stock ticker $CYTK but provides no directional view or market analysis.
HIGH
About CYTK Analyst Coverage
Buzzberg tracks CYTK (Cytokinetics Inc.) across 3 sources. 4 bullish vs 0 bearish calls from 3 analysts. Sentiment: predominantly bullish (27%). 15 total trade ideas tracked. Past 7 days: 1 bullish, 1 watch. Latest voices: seedy19tron, asklivermore, A May MD.